STAT+: Makers of rare disease drugs seek exemption from Trump’s price-cut pilots

Biotech companies are lobbying the Trump administration to exclude rare disease treatments from Medicare price-lowering pilots. The Rare Disease Company Coalition met with the White House Office of Management and Budget to discuss exemptions from Trump’s plan to align U.S. drug prices with those in other countries through a most-favored nation policy.